RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemiaDavid Koschut, Dean Nižetić|Oncogene|2020Cited by 15
RAS activation via CRLF2 signaling is a widespread mechanism in Down syndrome acute lymphoblastic leukemia regardless of RAS mutationsDavid Koschut, Dean Nižetić|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 0